📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-09 12:01
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
50 announcements match the current filters (relevance ≥ 5).
Associate Themis Medicare Downgraded to CARE BB+; Sold GTBL Stake for ₹100 Cr
CARE Ratings downgraded the bank facilities of associate company Themis Medicare Limited (TML), lowering long-term facilities of ₹77.39 crore to 'CARE BB+; Stable' from 'CARE BBB-; Negative' and short-term facilities of ₹48.50 crore to 'CARE A4+' from 'CARE A3'. The downgrade was driven by sharp operational deterioration, including an operating loss (PBILDT loss) of ₹51.43 crore in Q1FY27 following revenue and debtor write-offs. Importantly for Gujarat Themis Biosyn (GTBL), the rating report discloses that TML sold part of its investment in GTBL to promoters, generating ₹100 crore in liquidity, while promoter share pledge rose to 43% as of June 30, 2026 to finance the purchase.
Confidence: HIGH
What changedCARE Ratings downgraded credit ratings across ₹125.89 crore of bank facilities for associate entity Themis Medicare Limited, citing severe margin erosion and write-offs.
Why it mattersFinancial distress at associate/parent entity Themis Medicare has already triggered the sale of GTBL shares worth ₹100 crore and increased promoter pledge to 43%, signaling governance and contagion risks for GTBL.
Downgraded Long-Term Facilities: ₹77.39 croreDowngraded Short-Term Facilities: ₹48.50 croreTML Q1FY27 PBILDT Loss: ₹51.43 croreLiquidity Raised via GTBL Stake Sale: ₹100 crorePromoter Share Pledge (June 30, 2026): 43%
📅 Short termNegative sentiment may spill over to Gujarat Themis Biosyn due to promoter pledge reaching 43% and related-party financial pressures at Themis Medicare.
📈 Long termWhile Gujarat Themis Biosyn maintains profitable standalone operations, promoter-level leverage and group distress create structural overhangs regarding capital allocation and ownership stability.
⚠ Risk flags
- Promoter share pledge at 43% as of June 30, 2026
- Severe operating losses and write-offs at related associate entity
- Potential risk of further share supply if group liquidity strains persist
Key Highlights
Long-term bank facilities of ₹77.39 crore downgraded to CARE BB+ (Stable) from CARE BBB- (Negative)
Short-term facilities of ₹48.50 crore downgraded to CARE A4+ from CARE A3
TML reported a consolidated PBILDT loss of ₹51.43 crore in Q1FY27 due to debtor and revenue write-offs
TML sold part of its GTBL shareholding to promoters to raise ₹100 crore of liquidity cushion
Promoter holding pledge increased to 43% as on June 30, 2026 to finance the GTBL share acquisition
👀 What to Watch
Track subsequent shareholding filings of Gujarat Themis Biosyn to monitor the promoter group pledge levels and any further secondary market dilution from parent group entities.
Gujarat Themis AGM: Shareholders Approve Preferential Issue & Borrowings; 1 Item Fails
Gujarat Themis Biosyn Limited released the scrutinizer's report for its 45th Annual General Meeting held on September 30, 2026. Shareholders approved Resolution 8 for raising funds via a preferential equity issue with 99.9987% total votes in favor. However, Resolution 7 (approval to avail loans/guarantees from promoters for acquisition/growth) was rejected, securing only 40.1441% votes in favor due to promoter non-voting and 81.57% institutional votes against. Other standard resolutions, including financial statements, director re-appointments, and commission payouts, were approved.
Confidence: HIGH
What changedShareholders formally approved a preferential equity issue while voting down a resolution to source promoter debt/guarantees for growth acquisitions.
Why it mattersEnables the company to execute equity-based fundraising to support expansion, but limits internal promoter-backed financing flexibility for inorganic growth.
Total voting shares: 130151705Preferential issue approval rate: 99.9987%Promoter loan resolution approval rate: 40.1441%Overall voting turnout: 75.6420%
📅 Short termLimited direct market impact as AGM voting outcomes are operational, though the institutional pushback on promoter loans highlights active shareholder governance.
📈 Long termClear path for equity-led capital raising to support the planned fermentation capacity doubling (from 216 MT to 432 MT) and API integration.
⚠ Risk flags
- Institutional pushback on related-party promoter loan arrangements
- Dilution risk arising from the newly approved preferential issue
Key Highlights
Resolution 8 to raise funds via preferential equity issue passed with 99.9987% favorable votes (98,448,066 votes)
Resolution 7 for promoter loans/guarantees to fund acquisitions failed, receiving only 40.1441% votes in favor and 59.8559% against
Public institutions opposed Resolution 7 with 81.5739% against votes (12,633,908 votes), where promoters were interested parties and could not vote
Overall voter participation stood at 75.6420% across most resolutions on a base of 130,151,705 total shares
👀 What to Watch
Track subsequent company disclosures regarding the pricing, sizing, and allottees of the approved preferential issue, as well as alternative financing strategies after the promoter loan proposal was rejected.
Gujarat Themis revises preferential issue to raise ₹335 Cr at ₹404/share for Japan acquisition
Gujarat Themis Biosyn issued an AGM notice corrigendum updating its preferential equity issue to raise up to ₹335.00 crore by issuing 82,92,081 shares at ₹404 per share (including a ₹403 premium). The proceeds are primarily earmarked for debt repayment or redemption of NCDs of ₹310.00 crore used to fund the 100% equity acquisition of MicroBiopharm Japan Co., Ltd., with ₹25.00 crore reserved for general corporate purposes. Promoter entity Pharmaceutical Business Group (India) Ltd is investing ₹250.00 crore, raising total promoter shareholding from 59.33% to 60.25%. The AGM to approve this resolution is scheduled for September 30, 2026.
Confidence: HIGH
What changedThe company amended Resolution 8 to rectify its floor price calculation under SEBI ICDR, fixing the preferential issue at 82,92,081 shares at ₹404 per share to raise ₹335.00 crore.
Why it mattersThe fundraise of ₹335 crore significantly alters the capital structure to de-lever borrowings tied to the 100% acquisition of MicroBiopharm Japan Co., Ltd., with substantial promoter equity backing.
Total fundraise: Rs. 335,00,00,724Issue price per share: Rs. 404Allocation for acquisition debt/NCDs: Rs. 310,00,00,724Promoter entity investment: Rs. 250,00,00,884Total shares to be issued: 82,92,081
📅 Short termShareholder voting approval at the AGM on September 30, 2026, and receipt of allotment funds will be the immediate events to watch.
📈 Long termReplacing debt with equity for the acquisition of MicroBiopharm Japan strengthens the balance sheet and paves the way for global fermentation and API footprint expansion.
⚠ Risk flags
- Shareholder dilution from issuing 82.92 lakh new equity shares (expanding base from 13.01 cr to 13.84 cr shares)
- Execution and integration risks relating to the overseas acquisition of MicroBiopharm Japan
Key Highlights
Preferential issue size updated to ₹335.00 crore (82,92,081 equity shares at ₹404 per share)
₹310.00 crore allocated to repay/prepay debt or redeem NCDs incurred for the 100% acquisition of MicroBiopharm Japan Co., Ltd.
Promoter entity Pharmaceutical Business Group (India) Ltd to subscribe to shares worth ₹250.00 crore
Post-issue, total promoter shareholding increases from 59.33% to 60.25%
Issue price set at ₹404 per share, above the SEBI ICDR floor price of ₹403.82
👀 What to Watch
Track the voting outcome of Resolution 8 at the upcoming AGM on September 30, 2026, followed by updates on the operational integration of MicroBiopharm Japan.
GTBL Completes Acquisition of MicroBiopharm Japan for JPY 21.5 Billion
Gujarat Themis Biosyn Limited (GTBL) has completed the 100% acquisition of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) via its Japanese subsidiary, Themis Biosyn Japan Limited (TBJ), for JPY 21.5 billion. GTBL funded the deal by investing INR 475 Crores in capital contribution and INR 745 Crores via a loan to TBJ (under a loan agreement of up to INR 800 Crores). MBJ reported FY26 revenue of JPY 9.5 billion and operates three GMP-compliant manufacturing plants with FDA and PMDA approvals. This transformational cross-border acquisition materially diversifies GTBL from its historical customer concentration where two clients accounted for 98% of sales.
Confidence: HIGH
What changedGTBL has formally completed the acquisition of 100% equity in MicroBiopharm Japan Co., Ltd. after satisfying all regulatory and closing conditions.
Why it mattersThe deal represents a massive scale transformation relative to GTBL's quarterly revenue base (Rs 43.79 cr in Jun 2026), substantially reducing client concentration while expanding capabilities into precision fermentation, biologics, and global CDMO markets.
Total acquisition consideration: JPY 21.5 billionCapital contribution in TBJ: INR 475 CroresLoan extended to TBJ: INR 745 CroresLoan facility ceiling: Up to ₹800 CroresTarget FY26 revenue: JPY 9.5 billion
📅 Short termPositive sentiment given the formal closing of a major cross-border deal and expected immediate EPS accretion.
📈 Long termStructurally transforms GTBL from a concentrated intermediate manufacturer into a globally diversified, precision fermentation and biologics CDMO platform.
⚠ Risk flags
- High debt burden incurred to fund the transaction (loan up to INR 800 Crores)
- Cross-border integration and regulatory compliance across Japan and global markets
- Foreign exchange fluctuation risks (JPY/INR)
Key Highlights
Completed 100% acquisition of MicroBiopharm Japan for total consideration of JPY 21.5 billion
GTBL invested INR 475 Crores as capital and INR 745 Crores as a loan into wholly owned subsidiary TBJ
Executed an inter-company loan agreement of up to INR 800 Crores with TBJ
Acquired entity MBJ reported FY26 revenue of JPY 9.5 billion and operates 3 GMP-compliant sites
Approximately 40% of MBJ revenue is generated from outside Japan, expanding global CDMO presence
👀 What to Watch
Track the financial consolidation timeline in upcoming quarterly filings, alongside integration progress, debt servicing costs, and operational margin synergies.
Gujarat Themis Allots ₹585 Cr NCDs to Finance Japan Acquisition
Gujarat Themis Biosyn Limited has allotted unlisted, secured Non-Convertible Debentures (NCDs) aggregating ₹585 crore on a private placement basis. The issue is split into Series 1 (₹295 crore for 60 months at 10% p.a.) and Series 2 (₹290 crore for 18 months at 17.75% p.a.). Proceeds will primarily fund its wholly-owned subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd. The ₹585 crore borrowing is substantial relative to the company's Q1 FY27 revenue base of ₹43.79 crore.
Confidence: HIGH
What changedThe company has formally allotted ₹585 crore worth of secured NCDs across two tranches to finance an overseas acquisition in Japan.
Why it mattersThis represents a massive inorganic expansion into Japan, but the heavy debt load and high coupon (17.75% on ₹290 crore) significantly heighten financial leverage relative to quarterly revenues of ~₹44 crore.
Total NCD Issue Size: INR 585 CroresSeries 1 Size & Coupon: INR 295 Crores at 10% p.a.Series 2 Size & Coupon: INR 290 Crores at 17.75% p.a.Tenure (Series 1 / Series 2): 60 months / 18 months
📅 Short termMarket focus will center on debt terms, the 17.75% high-cost short-term borrowing rate, and forthcoming disclosures detailing MicroBiopharm Japan's valuation and financials.
📈 Long termIf successfully integrated, the Japanese acquisition could diversify Gujarat Themis beyond domestic intermediates and high client concentration; however, debt servicing poses substantial medium-term risk.
⚠ Risk flags
- High interest cost on Series 2 NCDs (17.75% p.a.) creates heavy debt service obligation
- Large borrowing (₹585 cr) relative to company size (Q1 FY27 revenue of ₹43.79 cr)
- Overseas cross-border M&A execution and integration risks
- Assets and personal promoter guarantee pledged as security
Key Highlights
Allotted ₹585 crore total NCDs across two series on private placement basis
Series 1 size is ₹295 crore with a 60-month tenure and 10% p.a. interest compounded monthly
Series 2 size is ₹290 crore with an 18-month tenure at an elevated coupon of 17.75% p.a.
Proceeds to fund the acquisition of MicroBiopharm Japan Co., Ltd via Japanese subsidiary
👀 What to Watch
Track the completion timeline and valuation of the MicroBiopharm Japan acquisition, along with the cash flow impact from the high interest burden (17.75% on Series 2).
Board approves up to ₹585 Cr NCD fundraise via private placement
Gujarat Themis Biosyn's Board of Directors has approved the issuance of unlisted Non-Convertible Debentures (NCDs) aggregating up to ₹585 Crores on a private placement basis. This is a very large borrowing facility relative to the company's single-quarter revenue of ₹43.79 Crores in Jun 2026 and its target revenue scale of over ₹250 Crores. The specific coupon, maturity, security charge, and issuance schedule will be determined and disclosed in due course upon allotment.
Confidence: HIGH
What changedThe Board approved raising debt of up to ₹585 Crores via unlisted NCDs, establishing a sizeable borrowing ceiling.
Why it mattersA ₹585 Crore debt limit is massive relative to recent quarterly revenue (₹43.79 Cr in Jun 2026), indicating potentially aggressive capex or inorganic growth plans, alongside a substantial shift in the company's leverage profile.
NCD borrowing limit: INR 585 CroresJun 2026 quarterly revenue: 43.79 crListing status of NCDs: No
📅 Short termMarket participants will likely seek clarity on the end-use of funds, coupon rate, and leverage impact as individual tranches are allotted.
📈 Long termIf deployed into high-return capacity expansions or acquisitions, it could significantly scale business operations, though it introduces debt servicing and balance-sheet risk.
⚠ Risk flags
- Substantial increase in debt leverage relative to operational scale
- Commercial terms like coupon rate and asset security are not yet disclosed
- Customer concentration risk remains high (top 2 clients represent 98% of sales)
Key Highlights
Approved borrowing limit of up to ₹585 Crores via Non-Convertible Debentures (NCDs)
Proposed to be issued on a private placement basis
The debentures are proposed to be unlisted
Coupon rate, tenure, and security charges to be disclosed at subsequent allotment stages
👀 What to Watch
Track subsequent filings for the exact utilization of proceeds (capex, M&A, or refinancing), interest cost, and debt repayment timelines.
Gujarat Themis Biosyn approves Rs 335 Cr preferential issue at Rs 408 per share
The Board of Directors of Gujarat Themis Biosyn has approved a preferential equity issue to raise up to Rs 335.00 crore. The company will issue up to 82,10,786 fully paid-up equity shares of face value Re 1 each at an issue price of Rs 408 per share (including Rs 407 premium). Promoter entity Pharmaceutical Business Group (India) Limited will subscribe to Rs 250.00 crore (61,27,453 shares), while marquee non-promoter investors including Dr. Yusuf Khwaja Hamied and institutional funds will invest the remaining Rs 85.00 crore.
Confidence: HIGH
What changedThe board approved a major capital raise of Rs 335 crore via preferential allotment to promoter and select non-promoter institutional/HNI investors.
Why it mattersA fundraise of Rs 335 crore is massive relative to recent quarterly revenue (Rs 43.79 Cr in Q1 FY27), providing substantial growth capital for the company's ongoing fermentation capacity doubling and API forward integration.
Total Fundraise Amount: Rs 335,00,00,688Shares to be Issued: 82,10,786Issue Price per Share: Rs 408Promoter Contribution: Rs 250,00,00,824Non-promoter Contribution: Rs 85,00,00,864
📅 Short termPositive sentiment driven by strong promoter backing (Rs 250 Cr) and participation from marquee pharmaceutical investors like Dr. Yusuf Khwaja Hamied.
📈 Long termStrengthens the balance sheet significantly, providing abundant liquidity to fund capacity expansion from 216 MT to 432 MT and support API launches.
⚠ Risk flags
- Equity dilution of existing minority shareholders
- Shareholder and regulatory approvals pending
Key Highlights
Approved preferential issue of up to 82,10,786 equity shares at Rs 408 per share, raising up to Rs 335.00 crore
Promoter entity Pharmaceutical Business Group (India) Ltd to invest Rs 250.00 crore (61,27,453 shares)
Non-promoter investors include Yusuf Khwaja Hamied (Rs 10.00 cr) and Special Situation/ISAF funds (Rs 75.00 cr)
Issue price of Rs 408 is near the current market price of Rs 422.10, subject to shareholder and regulatory approvals
👀 What to Watch
Track shareholder approval via upcoming postal ballot/EGM and subsequent stock exchange in-principle approvals, as well as management disclosures regarding capex and utilization of proceeds.
Gujarat Themis Biosyn raises ₹750 Cr via QIP at ₹354/share; allots 2.12 Cr shares
Gujarat Themis Biosyn Limited has successfully concluded its Qualified Institutions Placement (QIP), raising ₹749.99 crore. The Fund-Raising Committee approved the allotment of 2,11,86,440 equity shares of face value ₹1 each at an issue price of ₹354 per share (including a 4.98% discount to the floor price). This expands the total paid-up equity share capital by 19.44% to 13,01,51,705 shares. Key institutional participants include Quant Mutual Fund, Kotak Mahindra Life Insurance, Ayushmat Ltd, and Capri Global Capital.
Confidence: HIGH
What changedThe company completed a ₹750 crore QIP fundraise, expanding its equity base from 10.89 crore shares to 13.01 crore shares.
Why it mattersThe ₹750 crore fundraise significantly strengthens the balance sheet (representing more than 4x its annualized revenue run-rate of ~₹175 crore), providing substantial growth capital for upcoming fermentation and API capacity expansions.
Total fundraise amount: ₹749.99 crIssue price per share: ₹354Shares allotted: 2,11,86,440Post-issue equity shares: 13,01,51,705Equity dilution (post-issue base): 16.28%
📅 Short termThe successful closure of the QIP with reputed domestic institutional investors (DIIs) is positive, though short-term market adjustments may reflect the ₹354 issue price and 16.28% equity dilution.
📈 Long termProvides strong capital backing to fund ongoing capex in high-value APIs and fermentation capacity doubling (from 216 MT to 432 MT), driving structural growth.
⚠ Risk flags
- Equity dilution of ~16.28% on post-issue capital base
- Execution risk in deploying large capital effectively
Key Highlights
Allotted 2,11,86,440 equity shares at an issue price of ₹354 per share, raising ₹749.99 crore
Issue price of ₹354 includes a discount of ₹18.57 per share (4.98%) to the SEBI floor price
Paid-up share capital increased from ₹10.89 crore (10.89 crore shares) to ₹13.01 crore (13.01 crore shares)
Quant Small Cap Fund allocated 25.67% and Kotak Mahindra Life Insurance allocated 13.33% of the issue
👀 What to Watch
Track subsequent company disclosures regarding the specific deployment schedule of the ₹750 Cr proceeds toward fermentation capacity expansion and API integration, alongside post-issue shareholding pattern changes.
Gujarat Themis Closes ~Rs 750 Cr QIP at Rs 354/Share (4.98% Discount)
Gujarat Themis Biosyn Limited has concluded its Qualified Institutions Placement (QIP) on August 28, 2026. The Fund-Raising Committee approved the allotment of 2,11,86,440 equity shares of face value Rs 1 each at an issue price of Rs 354 per share (including a premium of Rs 353 per share). The issue price reflects a 4.98% discount (Rs 18.57 per share) to the SEBI floor price of Rs 372.57. Total capital raised from institutional buyers amounts to approximately Rs 750 crore.
Confidence: HIGH
What changedThe company has finalized its QIP issue price and share allocation, successfully closing the fundraise opened on August 25, 2026.
Why it mattersThe ~Rs 750 crore equity infusion significantly bolsters the balance sheet and liquidity, supporting capital expenditure for API forward integration and capacity doubling, though it entails equity dilution.
Total fundraise value: Rs ~750 crShares to be allotted: 2,11,86,440Issue price: Rs 354 per shareFloor price: Rs 372.57 per shareIssue discount: 4.98%
📅 Short termAllotment and listing of 2.12 crore new shares will expand the institutional shareholder base and trading float.
📈 Long termSubstantial capital inflow provides full funding visibility for planned fermentation capacity expansion to 432 MT and forward integration into high-value APIs.
⚠ Risk flags
- Equity dilution for existing shareholders due to issuance of 2.12 crore new shares.
- High customer concentration risk remains (top 2 clients historically account for ~98% of sales).
Key Highlights
QIP issue closed on August 28, 2026 following receipt of institutional funds and applications.
Approved allotment of 2,11,86,440 equity shares of face value Rs 1 each.
Issue price fixed at Rs 354 per share, implying a total capital raise of ~Rs 750 crore.
Issue price is at a 4.98% discount (Rs 18.57 per share) to the floor price of Rs 372.57 per share.
👀 What to Watch
Track the formal allotment and listing of the new shares, along with management updates on deployment of the ~Rs 750 crore proceeds towards ongoing fermentation capacity expansion (doubling from 216 MT to 432 MT).
Gujarat Themis Biosyn Opens QIP; Sets Floor Price at ₹372.57 Per Share
Gujarat Themis Biosyn Limited approved the opening of its Qualified Institutions Placement (QIP) on August 25, 2026. The board set the SEBI ICDR floor price at ₹372.57 per equity share (face value ₹1 each), representing a 9.3% discount to the recent market price of ₹410.90. The company may, at its discretion, offer a discount of up to 5% on the floor price. The issue follows shareholder approval granted via a special resolution on August 22, 2026.
Confidence: HIGH
What changedGujarat Themis Biosyn has officially launched its QIP equity fundraise with a floor price of ₹372.57 per share.
Why it mattersThe fundraise will bring fresh institutional equity capital to support the company's business plans (including its ongoing capacity expansion to 432 MT), accompanied by equity dilution for existing shareholders.
Floor Price: ₹ 372.57 per shareShare Face Value: ₹ 1Max Permissible Discount: 5%Relevant Date: 25th August, 2026
📅 Short termStock price may adjust towards the placement price as the book-building process concludes and final allocations are made.
📈 Long termCapital raised strengthens the balance sheet to fund ongoing fermentation capacity doubling and API forward integration projects.
⚠ Risk flags
- Equity dilution for existing public shareholders
- Capital deployment and execution timeline risk on new projects
Key Highlights
QIP issue opened on August 25, 2026, following board and shareholder approvals.
SEBI ICDR floor price determined at ₹372.57 per equity share of face value ₹1.
Discretionary discount of up to 5% allowed on the determined floor price.
Relevant date for the pricing formula fixed as August 25, 2026.
👀 What to Watch
Track subsequent filings for the final issue price, total funds raised, and the list of institutional allottees upon QIP closure.
Gujarat Themis Biosyn Shareholders Approve QIP and NCD Fundraise via Postal Ballot
Gujarat Themis Biosyn Limited has announced the successful passing of three special resolutions via postal ballot e-voting. Shareholders approved enabling resolutions to raise funds through a Qualified Institutions Placement (QIP) of equity shares and via private placement of Non-Convertible Debentures (NCDs) / debt securities. The QIP resolution received 99.97% votes in favor (77,845,234 votes), while the NCD resolution received 99.97% approval (77,844,780 votes). Total voting turnout stood at 71.46% of outstanding shares.
Confidence: HIGH
What changedShareholders formally approved enabling resolutions to raise capital through QIP and debt instruments.
Why it mattersProvides management with the enabling authority to raise external capital to support ongoing capex and capacity expansion programs.
Total shares outstanding: 108965265Total votes polled: 77865914Voter turnout: 71.4594%QIP approval rate: 99.9734%NCD approval rate: 99.9729%
📅 Short termClearance of enabling resolutions positions the company to launch a fundraise depending on market conditions.
📈 Long termSecuring equity or debt financing will provide headroom for planned growth initiatives, including fermentation capacity expansion and API integration.
⚠ Risk flags
- Potential equity dilution risk if and when the QIP is executed
Key Highlights
Resolution for equity fundraise via Qualified Institutions Placement (QIP) approved with 99.9734% votes in favour.
Private placement of NCDs and debt securities approved with 99.9729% votes in favour.
Amendment to the Articles of Association approved with 99.9969% votes in favour.
Total voter participation was 71.4594%, with 77,865,914 votes polled across 108,965,265 total shares.
👀 What to Watch
Track future board disclosures regarding the exact quantum, floor price, and timing of any upcoming QIP or debt issuance.
Q1 PAT Rises 22% to ₹11.1 Cr; Management Outlines ₹3,000 Cr Global Acquisition Roadmap
Gujarat Themis Biosyn reported a 22.1% YoY increase in Q1 FY27 revenue to ₹43.8 crore, driven by robust volume growth. EBITDA rose 49.4% YoY to ₹20.8 crore with margins expanding 867 bps to 47.5%, while PAT grew 22.1% YoY to ₹11.1 crore. Management detailed its transformational M&A strategy, including the acquisition of MicroBiopharm Japan for precision fermentation capabilities and 13 global anti-TB/anti-infective brands from Sanofi across 55 countries. Addressing financing of the estimated ₹3,000 crore acquisition outlay, management highlighted that foreign debt costs will be significantly lower than Indian rates and expected the assets to be cash flow positive.
Confidence: HIGH
What changedGujarat Themis published its Q1 FY27 earnings transcript detailing operational performance and execution plans for its large-scale overseas acquisitions.
Why it mattersThe company is transitioning from a localized intermediate manufacturer into an integrated, global fermentation-based CDMO player with branded formulations in 55 export markets.
Q1 FY27 Revenue: ₹43.8 crQ1 FY27 EBITDA Margin: 47.5%Q1 FY27 PAT: ₹11.1 crSanofi Acquired Brands: 13 brandsSanofi Geographic Reach: 55 countries
📅 Short termOperational momentum is solid with EBITDA margins at 47.5%, while market focus will remain on the execution and fundraise structuring for the announced overseas deals.
📈 Long termIf successfully integrated, the twin acquisitions of MicroBiopharm Japan and Sanofi's brand portfolio will exponentially scale revenue from the historic ₹150-180 crore annual run rate to over ₹1,000 crore.
⚠ Risk flags
- High leverage and equity dilution risk related to proposed ₹2,000 cr debt and ₹1,000 cr QIP
- Long regulatory approval gestation (long stop date June next year) across 50+ jurisdictions for the Sanofi transaction
- Customer and supply chain concentration risks during the ongoing integration phase
Key Highlights
Q1 FY27 revenue grew 22.1% YoY to ₹43.8 crore from ₹35.9 crore in Q1 FY26
EBITDA increased 49.4% YoY to ₹20.8 crore, expanding EBITDA margins by 867 bps to 47.5%
PAT increased 22.1% YoY to ₹11.1 crore compared to ₹9.1 crore in the year-ago period
Acquiring 13 anti-TB and anti-infective brands from Sanofi covering 55 countries across EMEA, with closing targeted before June next year
Acquiring MicroBiopharm Japan to add advanced capabilities in ADCs, plasmids, peptides, and enzyme engineering
👀 What to Watch
Track the closing timeline of the MicroBiopharm Japan deal and regulatory approvals across 55 countries for the Sanofi asset carve-out, along with the pricing and dilution terms of the proposed ₹1,000 crore QIP.
GUJTHEM Q1 PAT up 22%; Announces ~INR 1,300 Cr Japan Acquisition & EUR 158 Mn Sanofi Deal
Gujarat Themis Biosyn (GUJTHEM) reported a strong Q1 FY27 with revenue of Rs 43.8 Cr (+22.1% YoY) and EBITDA margins expanding 867 bps to 47.5%. The company announced two massive, transformative acquisitions: MicroBiopharm Japan for ~INR 1,300 Cr and a Sanofi brand portfolio for ~EUR 158 Mn. These deals are highly material, collectively exceeding 15x the company's FY26 revenue of Rs 165.8 Cr. The company has also completed its fermentation capacity doubling to 432 MT and is commissioning an 18 MW hybrid power plant to optimize costs.
Confidence: HIGH
What changedGUJTHEM is pivoting from a small-scale intermediate manufacturer to a global CDMO player through two massive international acquisitions and a doubling of its domestic fermentation capacity.
Why it mattersThe acquisitions provide immediate global market access and high-value technology (peptides, oncology), potentially re-rating the business by diversifying its revenue base and moving it up the value chain into APIs and finished dosages.
MicroBiopharm Deal Value: ~INR 1,300 CrSanofi Portfolio Deal Value: ~EUR 158 MnQ1 FY27 EBITDA Margin: 47.48%New Fermentation Capacity: 432 MTQ1 FY27 Revenue: Rs 43.8 CrHybrid Power Capacity: 18 MW
📅 Short termPositive sentiment is expected due to the scale of inorganic growth announcements and strong margin expansion in Q1 results.
📈 Long termStructural transformation into a global CDMO; long-term success depends on the successful integration of Japanese and European assets and managing the debt taken for these acquisitions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of large international acquisitions
- High client concentration (98% revenue from top 2 clients)
- Potential balance sheet leverage from ~INR 2,700 Cr+ total acquisition cost
Key Highlights
Acquisition of MicroBiopharm Japan for JPY 21.5 Bn (~INR 1,300 Cr), adding ~INR 575 Cr in revenue.
Acquisition of 13 Sanofi brands for ~EUR 158 Mn, covering 55+ countries in TB and anti-infectives.
Q1 FY27 EBITDA grew 49.4% YoY to Rs 20.8 Cr, driven by volume-led economies of scale.
Fermentation capacity expansion from 216 MT to 432 MT is now complete.
18 MW Hybrid wind-solar power project underway to reduce grid dependence and power costs.
👀 What to Watch
Monitor the regulatory approval timeline for the MicroBiopharm acquisition (expected Q2 FY27) and the funding structure (debt/equity mix) for these large-scale deals. Watch for the integration of Sanofi's brands and their impact on reducing the current 98% revenue concentration from two major clients.
GUJTHEM Q1 FY27 PAT Up 22% YoY to ₹11.07 Cr; Revenue Reaches ₹43.79 Cr
Gujarat Themis Biosyn reported a steady Q1 FY27 with standalone revenue growing 22% YoY to ₹43.79 Cr, up from ₹35.87 Cr in Q1 FY26. Net profit followed a similar trajectory, rising 22% YoY to ₹11.07 Cr. The company maintained robust profitability with a Profit Before Tax (PBT) margin of 34.5%. Consolidated results show that newly formed subsidiaries in Japan and Ireland are currently non-operational, contributing nil to the top line.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, showing sustained YoY growth in both revenue and profitability following the commercialization of new APIs in mid-2025.
Why it mattersThe results confirm the successful stabilization of new fermentation-based APIs (Rifapentine and Rifamycin) and demonstrate the company's ability to maintain high margins despite rising employee and power costs.
Revenue (Q1 FY27): ₹43.79 CrNet Profit (Q1 FY27): ₹11.07 CrYoY Revenue Growth: 22.07%PBT Margin: 34.5%EPS: ₹1.02
📅 Short termThe stock may react positively to the double-digit YoY growth in earnings and the maintenance of healthy operating margins.
📈 Long termLong-term value depends on the successful doubling of capacity to 432 MT and the operationalization of international subsidiaries to diversify revenue streams.
⚠ Risk flags
- Extreme client concentration (98% of revenue from two clients)
- Non-operational status of foreign subsidiaries
- High dependency on fermentation-based intermediates which face Chinese competition
Key Highlights
Revenue from operations increased 22.07% YoY to ₹43.79 Cr.
Net Profit (PAT) rose to ₹11.07 Cr compared to ₹9.06 Cr in the year-ago quarter.
Profit Before Tax (PBT) stood at ₹15.17 Cr, representing a 34.5% margin on total income.
Earnings Per Share (EPS) improved to ₹1.02 from ₹0.83 in Q1 FY26.
Total expenses increased to ₹28.76 Cr, with raw material costs accounting for ₹7.73 Cr.
👀 What to Watch
Investors should monitor the execution of the fermentation capacity doubling (from 216 MT to 432 MT) expected by the end of FY26 and track if the high client concentration (98% from two clients) begins to diversify with new API launches.
₹1500 Cr Debt Fundraise Limit and Promoter Debt-to-Equity Conversion Proposed
Gujarat Themis Biosyn (GUJTHEM) has convened an EGM on August 22, 2026, to seek shareholder approval for a massive ₹1500 Cr debt fundraise limit via NCDs. This proposed limit is approximately 38.6x its FY24 revenue of ₹38.86 Cr, signaling a potential for significant inorganic growth or massive capital expenditure. Additionally, the company is seeking approval for material related party transactions with promoters, including a provision to convert outstanding borrowings into equity shares. An amendment to the Articles of Association is also proposed to simplify the process for further issuance of share capital.
Confidence: HIGH
What changedThe company is moving from a small-scale operation (₹38.86 Cr revenue) to creating a massive capital buffer (₹1500 Cr) and enabling flexible equity issuance mechanisms.
Why it mattersThe scale of the proposed fundraise is disproportionately large compared to the current business size, suggesting a major strategic shift or M&A. The debt-to-equity conversion provides a path for promoters to increase or maintain stakes while funding the company.
Proposed Debt Limit: ₹1500 CrDebt Limit vs FY24 Revenue: 38.6xFY24 Revenue: ₹38.86 CrPromoter Holding: 70.86%Current Capacity: 216 MTEGM Date: August 22, 2026
📅 Short termThe stock may see volatility as the market digests the magnitude of the ₹1500 Cr fundraise and the implications of the debt-to-equity conversion.
📈 Long termIf the capital is deployed effectively for the 100% capacity expansion or M&A, it could structurally re-rate the company; however, the high client concentration (98% from two clients) remains a structural risk.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Potential equity dilution from debt-to-equity conversion
- High debt-to-revenue ratio if limit is fully utilized
- Extreme client concentration (98% of sales to 2 clients)
Key Highlights
Proposed issuance of Non-Convertible Debentures (NCDs) and debt securities up to a principal amount of ₹1500 Crores.
Provision to convert promoter borrowings from Pharmaceutical Business Group India Ltd and Dr. Sachin Patel into equity shares.
Amendment to Article 13 of the Articles of Association to remove the mandatory 'registered valuer' wording for specific share issuances.
EGM scheduled for August 22, 2026, to vote on these special and ordinary resolutions.
Company is currently doubling fermentation capacity from 216 MT to 432 MT, targeted for completion by FY26.
👀 What to Watch
Investors should closely monitor the EGM results and subsequent board announcements regarding the specific utilization of the ₹1500 Cr debt limit. The potential for equity dilution through the debt-to-equity conversion clause for promoters is a critical factor to watch.
47.02% stake in Gujarat Themis Biosyn indirectly encumbered via promoter pledge
CTL Trusteeship has disclosed an indirect encumbrance on 5,12,40,000 shares of Gujarat Themis Biosyn Limited (GUJTHEM), representing 47.02% of its total capital. This encumbrance arises from a pledge and non-disposal undertaking (NDU) created by Vividhmargi Investments Private Limited (VIPL) over its 98.988% stake in Pharmaceutical Business Group (India) Limited (PBGIL), the primary promoter entity. The action secures debentures issued by OSS Software Solutions Labs Private Limited under a deed dated June 25, 2026. Effectively, nearly the entire promoter-level holding in the company is now indirectly encumbered to secure third-party debt.
Confidence: HIGH
What changedA significant portion of the promoter's indirect holding in GUJTHEM has been pledged and placed under a non-disposal undertaking to secure debentures issued by a third party.
Why it mattersHigh promoter-level leverage is a risk factor; if the underlying debt is not serviced, it could lead to forced liquidation of the promoter's stake or a change in control.
Indirectly encumbered stake: 47.02%Shares held by PBGIL: 5,12,40,000VIPL stake in PBGIL: 98.988%Pledge effective date: June 29, 2026
📅 Short termNeutral to cautious; the market may react to the high level of indirect promoter pledge as it introduces a layer of financial risk.
📈 Long termStructural risk exists regarding promoter stability and potential ownership shifts if the holding company debt is not managed.
⚠ Risk flags
- High indirect promoter pledge (47.02%)
- Potential for forced liquidation if debentures default
- Third-party debt security
Key Highlights
Indirect encumbrance created on 5,12,40,000 equity shares of the Target Company
Encumbrance covers 47.02% of the total issued and paid-up share capital of GUJTHEM
Vividhmargi Investments pledged 51% and placed 47.988% under NDU in the promoter entity PBGIL
The arrangement secures debentures issued by OSS Software Solutions Labs Private Limited effective June 29, 2026
👀 What to Watch
Monitor the financial health of the issuer (OSS Software Solutions Labs) and any further disclosures regarding the purpose of this leverage. High promoter-level encumbrance can increase stock volatility during market downturns.
GUJTHEM Seeks Shareholder Approval for Fundraise via QIP to Support Expansion
Gujarat Themis Biosyn (GUJTHEM) has issued a postal ballot notice to seek shareholder approval for raising funds through a Qualified Institutions Placement (QIP). This resolution supersedes a previous special resolution passed on July 8, 2026. The fundraising is likely intended to support the company's ongoing 100% capacity expansion from 216 MT to 432 MT. The e-voting period is scheduled from July 24 to August 22, 2026, with results expected by August 25, 2026.
Confidence: HIGH
What changedThe company is seeking fresh shareholder approval for a QIP, superseding a resolution passed earlier in July 2026, indicating a formalization of its capital-raising plans.
Why it mattersThe fundraise is critical for GUJTHEM's strategy to scale from a small-cap intermediate manufacturer to a larger API player, aiming for a nearly 6x increase in revenue compared to FY24 levels.
FY24 Revenue: ₹38.86 CrTarget Operating Income: >₹250 CrCapacity Expansion: 100% (216 MT to 432 MT)Voting End Date: August 22, 2026Results Declaration Date: August 25, 2026
📅 Short termThe stock may see increased interest as institutional participation via QIP often signals confidence in the company's growth trajectory.
📈 Long termSuccess depends on the timely execution of the 432 MT capacity expansion and reducing the 98% revenue concentration from its top two clients.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders
- High client concentration (98% of revenue from Lupin and Optrix)
- Execution risk in doubling capacity by FY26
Key Highlights
Proposed fundraise via QIP to issue equity shares of face value ₹1 each.
E-voting period commences on July 24, 2026, and ends on August 22, 2026.
Company is doubling fermentation capacity from 216 MT to 432 MT by FY26.
Targeting total operating income exceeding ₹250 Cr, a significant jump from FY24 revenue of ₹38.86 Cr.
Cut-off date for voting eligibility was set as July 10, 2026.
👀 What to Watch
Monitor the outcome of the postal ballot on August 25, 2026, and watch for subsequent disclosures regarding the QIP size and floor price to assess potential equity dilution.
₹3,000 Cr Acquisitions Trigger CARE Rating Watch with Negative Implications
CARE Ratings has placed Gujarat Themis Biosyn (GTBL) on 'Rating Watch with Negative Implications' following the announcement of two massive acquisitions totaling approximately ₹3,000 crore. The company plans to acquire MicroBiopharm Japan for ~₹1,300 crore and a Sanofi anti-TB portfolio for ~₹1,700 crore, a combined outlay representing 10x the company's tangible net worth. While GTBL plans to fund this partly through a ₹1,000 crore QIP, the rating agency cited concerns over funding uncertainty and high leverage. The company has formally dissented, arguing that the acquisitions will be EBITDA-accretive and that QIP roadshows are already in progress.
Confidence: HIGH
What changedThe company's credit rating outlook was moved from stable to 'Rating Watch with Negative Implications' due to the financial risks of two transformative acquisitions.
Why it mattersThe acquisitions are massive relative to the company's current size (10x net worth) and could either exponentially scale the business or severely strain the balance sheet if the ₹1,000 crore fundraise or integration fails.
Total Acquisition Value: ₹3,000 crorePlanned QIP Size: ₹1,000 croreAcquisition vs Net Worth: ~10xNet Debt/EBITDA: 2.25Target Operating Income: >₹250 crore
📅 Short termThe 'Negative Watch' may cause short-term price volatility as the market assesses the risk of equity dilution from the QIP and the high debt requirements.
📈 Long termIf successfully integrated, these acquisitions could transform GTBL from a niche intermediate manufacturer into a global API and brand player, though execution risk is high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High leverage (10x net worth acquisition)
- Funding uncertainty for the ₹3,000 cr outlay
- Extreme customer concentration (98% revenue from 2 clients)
- Execution risk in global M&A
Key Highlights
Acquisition of MicroBiopharm Japan Co., Ltd. for ¥1.5 Billion (~₹1,300 crore) expected by Q2FY27.
Asset purchase agreement with Sanofi for anti-TB and anti-infective brands for €158 million (~₹1,700 crore).
Total acquisition value is approximately 10 times the company's current tangible net worth.
Planned ₹1,000 crore Qualified Institutional Placement (QIP) to manage the funding mix.
Current Net Debt/EBITDA stands at 2.25, with potential for significant increase depending on final funding structure.
👀 What to Watch
Monitor the successful execution and pricing of the ₹1,000 crore QIP, as it is critical for the acquisition timeline. Investors should also track regulatory approvals for the Japanese and Sanofi transactions and the subsequent impact on the debt-to-equity ratio.
CARE places GUJTHEM on Negative Watch following ₹3,000 Cr Acquisition Plans
CARE Ratings has placed Gujarat Themis Biosyn's 'BBB' rating on 'Rating Watch with Negative Implications' due to two massive proposed acquisitions totaling approximately ₹3,000 crore. These include the acquisition of MicroBiopharm Japan for ~₹1,300 crore and a Sanofi anti-TB portfolio for ~₹1,700 crore, which together represent over 10x the company's tangible net worth of ₹287.67 crore. The company plans to fund these via a ₹1,000 crore QIP and other yet-to-be-finalized structures. Management has formally dissented against this rating action, citing that it ignores structural de-risking and future cash flow additions.
Confidence: HIGH
What changedCARE Ratings has moved the company's credit rating from a stable outlook to 'Rating Watch with Negative Implications' following the announcement of massive global acquisitions.
Why it mattersThe acquisitions are transformative in scale but carry extreme financial risk as they are 10 times the company's current net worth. The rating watch reflects uncertainty regarding the funding structure and potential leverage deterioration.
Total Acquisition Value: ~₹3,000 croreAcquisition vs Net Worth: 1042%Proposed QIP Size: ₹1,000 croreTangible Net Worth (Mar 2026): ₹287.67 croreOverall Gearing (FY26): 0.56x
📅 Short termThe rating watch and the company's formal dissent may lead to short-term price volatility as the market assesses the funding risk of the ₹3,000 crore deals.
📈 Long termIf successfully integrated and funded without excessive dilution or debt, these acquisitions could exponentially scale the business; however, execution and integration risks are currently very high.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Extreme leverage risk (acquisitions 10x net worth)
- Funding uncertainty (QIP dependency)
- High customer concentration (98% revenue from 2 clients)
- International integration risk
Key Highlights
Proposed acquisition of MicroBiopharm Japan (MBJ) for ~₹1,300 crore (¥1.5 Billion) expected by Q2FY27.
Asset purchase agreement with Sanofi for anti-TB brands valued at ~₹1,700 crore (€158 million).
Total acquisition outlay of ~₹3,000 crore is roughly 10.4x the company's March 2026 net worth of ₹287.67 crore.
Company planning a ₹1,000 crore Qualified Institutional Placement (QIP) to fund the MBJ acquisition.
Overall gearing moderated to 0.56x as of March 31, 2026, compared to 0.12x in the previous year due to capex loans.
👀 What to Watch
Investors should closely monitor the successful completion of the ₹1,000 crore QIP and regulatory approvals for the Japanese and Sanofi acquisitions. The key risk to watch is the final debt-equity mix and the company's ability to service significantly higher debt levels post-acquisition.
47.02% Indirect Promoter Stake Encumbered via Pledge and Non-Disposal Undertaking
Pharmaceutical Business Group (India) Limited (PBGIL), a promoter entity holding 47.02% of Gujarat Themis Biosyn Limited (GTBL), has seen its entire holding indirectly encumbered. This resulted from Vividhmargi Investments Private Limited (VIPL) pledging 51% and entering a non-disposal undertaking for 47.98% of PBGIL's shares in favor of CTL Trusteeship Limited. The transaction is linked to a Debenture Trust Deed dated June 25, 2026. While the pledge is at the holding company level, it effectively places a lien on the majority of the promoter's interest in GTBL.
Confidence: HIGH
What changedA promoter-level holding company (VIPL) has encumbered its entire stake in the direct promoter (PBGIL), creating an indirect lien on GTBL's shares.
Why it mattersHigh promoter pledging is a significant risk factor as it can lead to forced selling or a change in control if the underlying debt obligations are not met, potentially causing high stock price volatility.
Total shares encumbered: 5,12,40,000% of GTBL equity: 47.02%Pledge in PBGIL: 51%NDU in PBGIL: 47.98%Date of creation: 29/06/2026
📅 Short termThe stock may face some pressure or volatility as the market reacts to the high level of indirect promoter pledging.
📈 Long termWhile the company is expanding capacity to 432 MT by FY26, the promoter-level debt adds a layer of structural risk that must be balanced against growth prospects.
⚠ Risk flags
- High promoter pledging (indirectly 47.02% of the company)
- Extreme client concentration (98% of revenue from two clients)
- Promoter-level debt obligations
Key Highlights
Indirect encumbrance created on 5,12,40,000 equity shares of GTBL
The encumbered stake represents 47.02% of the total issued and paid-up share capital
Pledge involves 25,24,245 shares (51%) and non-disposal undertaking involves 21,57,855 shares (47.98%) of the promoter entity PBGIL
Action taken in favor of CTL Trusteeship Limited pursuant to a Debenture Trust Deed dated June 25, 2026
The encumbrance was officially created on June 29, 2026
👀 What to Watch
Investors should monitor for any further disclosures regarding the purpose of the debt raised at the promoter level and watch for any signs of financial stress that could lead to an invocation of the pledge.
